| 存储条件 |
|---|
| Product Name | Pirh2 [D6-H10] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Androgen receptor N terminal interacting protein antibody Androgen receptor N-terminal-interacting protein antibody ARNIP antibody CH-rich-interacting match with PLAG1 antibody CHIMP antibody E3 ubiquitin-protein ligase Pirh2 antibody hARNIP antibody hPirh2 antibody p53 induced protein with a RING H2 domain antibody p53-induced RING-H2 protein antibody PIRH2E antibody PIRH2F antibody PRO1996 antibody RCHY1 antibody Ring finger and CHY zinc finger domain containing 1 E3 ubiquitin protein ligase antibody RING finger and CHY zinc finger domain-containing protein 1 antibody RING finger protein 199 antibody RNF199 antibody ZCHY antibody ZFP 363 antibody zinc finger CHY type antibody Zinc finger protein 363 antibody ZN363_HUMAN antibody ZNF363 antibody |
| Product description | Pirh2, also known as Androgen receptor N-terminal-interacting protein (ARNIP), ZN363 or CHIMP, has p53-induced ubiquitin-protein ligase activity, promoting p53 degradation. The protein physically interacts with p53 and the resulting degradation of p53 renders Pirh2 an oncogenic protein as the loss of p53 function contributes to malignant tumor development. The gene encoding for the protein maps to chromosome 4q21.1 and transcription of this gene is regulated by p53. Pirh2 expression decreases the level of p53 and a decrease of endogenous Pirh2 expression ups p53 levels. Pirh2 is therefore considered, together with MDM2, to be acting as a negative regulator of p53 function. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBICCIHCFC |
| WB:1:250~1:1000 ICC:1:100~1:200 IHC:1:20~1:100 FC:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. | |
| Species Reactivity | HumanRat |
| Concentration | 2mg/ml |
| Alternative Names | Androgen receptor N terminal interacting protein antibody Androgen receptor N-terminal-interacting protein antibody ARNIP antibody CH-rich-interacting match with PLAG1 antibody CHIMP antibody E3 ubiquitin-protein ligase Pirh2 antibody hARNIP antibody hPirh2 antibody p53 induced protein with a RING H2 domain antibody p53-induced RING-H2 protein antibody PIRH2E antibody PIRH2F antibody PRO1996 antibody RCHY1 antibody Ring finger and CHY zinc finger domain containing 1 E3 ubiquitin protein ligase antibody RING finger and CHY zinc finger domain-containing protein 1 antibody RING finger protein 199 antibody RNF199 antibody ZCHY antibody ZFP 363 antibody zinc finger CHY type antibody Zinc finger protein 363 antibody ZN363_HUMAN antibody ZNF363 antibody |
|---|---|
| Molecular Weight(MW) | 30 kDa |
| Cellular Localization | Nucleus. Nucleus speckle. Cytoplasm. |
| SwissProt ID | Q96PM5 |
|---|
Application
Fig1: Western blot analysis of Pirh2 on different cell lysate using anti-Pirh2 antibody at 1/1,000 dilution. Positive control： Line1: Hela Line2: A549 Line3: MCF-7 Line4: PC-12
Application
Fig2: ICC staining Pirh2 (green) and Actin filaments (red) in Hela cells. Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Pirh2 antibody. Counter stained with hematoxylin.
Application
Fig4: Flow cytometric analysis of PC-12 cells with Pirh2 antibody at 1/100 dilution (blue) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Hela, A549, MCF-7, PC-12 cell lysate, human tonsil tissue, Hela, PC-12. |
|---|---|
| Application Notes | WB:1:250~1:1000 ICC:1:100~1:200 IHC:1:20~1:100 FC:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
抱歉，暂无相关文献
